Hemophilia A is a severe bleeding disorder caused by a deficiency in c
lotting factor VIII (FVIII). A canine model that closely mimics the hu
man disease was used to determine if an adenoviral vector expressing a
human FVIII cDNA could be used to correct the hemophilia A phenotype.
Within 48 hours after peripheral vein administration of the vector to
FVIII-deficient dogs, the hemophilic phenotype was corrected, based o
n determination of the activated cloning time, the activated partial t
hromboplastin time, and the cuticle bleeding time, Direct measurement
of human FVIII in the dog plasma showed FVIII expression at amounts we
ll above the human therapeutic level, FVIII expression in treated dogs
was short-term, lasting 1 to 2 weeks, due to the development of a hum
an FVIII-specific inhibitor antibody response. These data provide the
first demonstration of in vivo gene therapy of hemophilia A. (C) 1996
by The American Society of Hematology.